Maximizing clinical benefit with trastuzumab

被引：25

作者：

Bell, R

Verma, S

Untch, M

Cameron, D

Smith, I

机构：

[1] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia

[2] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada

[3] Univ Munich, Munich, Germany

[4] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland

[5] Royal Marsden Hosp, London SW3 6JJ, England

来源：

SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 05期

关键词：

D O I：

10.1053/j.seminoncol.2004.07.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：35 / 44

页数：10

共 92 条

[1]

ABELOFF MD, 1995, SEMIN ONCOL, V22, P1

[2]

Bangemann N, 2000, ANN ONCOL, V11, P143

[3] Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) in patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC) [J].

Baselga, J. ;

Climent, M. A. ;

Lluch, A. ;

Hornedo, J. ;

Gascon, R. ;

Sanchez, A. T. ;

Guillem, V. ;

Cortes-Funes, H. ;

Regueiro, P. ;

Trigo, J. .

EJC SUPPLEMENTS, 2004, 2 (03) :132-132

[4] Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer:: Pivotal trials [J].

Baselga, J .

ONCOLOGY, 2001, 61 :14-21

[5]

Bauer-Kosinska B., 2003, EJC Supplements, V1, pS141, DOI 10.1016/S1359-6349(03)90496-4

[6]

BAYO JL, 2004, EJC SUPPL, V2, P129

[7]

BERNARDO G, 2002, ANN ONCOL, V13, P51

[8] Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial [J].

Blackstein, M ;

Vogel, CL ;

Ambinder, R ;

Cowan, J ;

Iglesias, J ;

Melemed, A .

ONCOLOGY, 2002, 62 (01) :2-8

[9]

Blum JL, 2001, CANCER, V92, P1759, DOI 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO

[10]

2-A

← 1 2 3 4 5 6 7 8 9 10 →